Many studies have confirmed that SRGN promotes tumor invasion and metastasis in colorectal cancer, non-small cell lung cancers, multiple myeloma, nasopharyngeal carcinoma, and breast cancer (Li et al., 2011; Korpetinou et al., 2013; Purushothaman and Toole, 2014; Guo et al., 2017; Xu et al., 2018). This evidence concerns the gene SRGN and plasma cell myeloma.